FDA greenlights novel agent for COPD maintenance therapy

Ensifentrine (Ohtuvayre), a first-in-class dual phosphodiesterase (PD)-3 and 4 inhibitor, is indicated for the maintenance treatment of COPD in adult patients. According to a manufacturer press release, the nebulized therapy exhibits combined bronchodilator and non-steroidal anti-inflammatory effects. Approval was based on data from the ENHANCE-1 and 2 trials, in which ensifentrine demonstrated significant improvements in lung function and reduced exacerbation risk compared with placebo.